- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Psyence Group Inc (2): Psyence RTO target receives reconnaissance licences | 1 | Stockwatch | ||
| Di | Psyence Group Inc.: Psyence Group's RTO Target, GoldCoast Resource Corp., Granted Offshore Reconnaissance License for Gold Exploration on Ghana's Shallow Continental Shelf | 988 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / January 27, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that its proposed reverse takeover target, GoldCoast Resource Corp. ("GoldCoast")... ► Artikel lesen | |
| 25.11.25 | XFRA EKW0: AUSSETZUNG/SUSPENSION | 125 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPSYENCE GROUP INC.... ► Artikel lesen | |
| 25.11.25 | Psyence Group Inc (2): Psyence enters definitive merger deal with GoldCoast | 3 | Stockwatch | ||
| 24.11.25 | Psyence Group Inc (2): Psyence Group to remain halted | 3 | Stockwatch | ||
| 24.11.25 | CSE Bulletin: Halted for Fundamental Change - Psyence Group Inc. (PSYG) | 273 | Newsfile | Toronto, Ontario--(Newsfile Corp. - Le 24 novembre/November 2025) - Trading in the shares of Psyence Group Inc. (PSYG) will remain halted pending receipt and review of acceptable documentation regarding... ► Artikel lesen | |
| PSYENCE GROUP Aktie jetzt für 0€ handeln | |||||
| 24.11.25 | Psyence Group Inc. Enters into Amalgamation Agreement with Goldcoast Resource Corp. | 464 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 24, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce that, further to its news release dated August 22, 2025, it has... ► Artikel lesen | |
| 18.10.25 | Psyence Group Inc (2): Psyence Group grants 721,448 RSUs | 1 | Stockwatch | ||
| 17.10.25 | Psyence Group Inc. Announces RSU Grants | 472 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / October 17, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it granted an aggregate of 721,448 restricted share units (each an "RSU")... ► Artikel lesen | |
| 22.08.25 | Psyence Group Inc (2): Psyence Group enters LOI to acquire GoldCoast | 3 | Stockwatch | ||
| 22.08.25 | XFRA EKW0: WIEDERAUFNAHME/RESUMPTION | 440 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 22.08.25 | Psyence Group Inc. Enters Into a Letter of Intent to Acquire Goldcoast Resource Corp. | 455 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / August 22, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it has entered into a letter of intent (the "LOI") to acquire all of the... ► Artikel lesen | |
| 07.07.25 | Psyence Group Inc. Closes Second Tranche of Non-Brokered Private Placement for Remaining Proceeds | 475 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / July 7, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), is pleased to announce that it has successfully closed the second tranche ("Tranche 2") of... ► Artikel lesen | |
| 23.04.25 | XFRA 8VC0,BC21,EKW0,1S90: AUSSETZUNG/SUSPENSION | 269 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILGREAT PLAINS MET.... ► Artikel lesen | |
| 23.04.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 23.04.2025 | 503 | Xetra Newsboard | The following instruments on XETRA do have their first trading 23.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.04.2025
Aktien
1 US7866231084 AB Sagax ADR
2 US36170Y1038... ► Artikel lesen | |
| 22.04.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.04.2025 | 597 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 22.04.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.04.2025ISIN NameCA00833F3079 AFRICAN... ► Artikel lesen | |
| 22.04.25 | XFRA ISIN CHANGE | 593 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA00833F3079 African Energy Metals Inc. 22.04.2025 CA5589221004 Magma Silver Corp. 23.04.2025 Tausch 1:1CA74449Q1063 Psyence... ► Artikel lesen | |
| 22.04.25 | CSE Bulletin: Consolidation - Psyence Group Inc. (PSYG) | 445 | Newsfile | Toronto, Ontario--(Newsfile Corp. - Le 21 avril/April 2025) - Psyence Group Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated... ► Artikel lesen | |
| 17.04.25 | Psyence Group Inc.: Psyence Group Announces Share Consolidation | 255 | GlobeNewswire (Europe) | TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence Group" or the "Company") (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share... ► Artikel lesen | |
| 09.04.25 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 09.04.2025 | 1.179 | Xetra Newsboard | The following instruments on XETRA do have their first trading 09.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 09.04.2025
Aktien
1 US83192D4025 Smartstop Self Storage... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,335 | -0,85 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen von "Buy" auf "Hold" abgestuft. Das Kursziel erhöhte Analyst Jan Koch in einer am Donnerstag vorliegenden Studie aber von 52 auf 54 US-Dollar.... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,400 | -1,41 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 37,650 | -1,83 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 69,98 | -1,02 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| IMMUNOVANT | 26,450 | +1,46 % | Immunovant Inc.: Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 | ||
| ALUMIS | 26,840 | -3,10 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 11,160 | -5,26 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,880 | +1,25 % | Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? | ||
| STRUCTURE THERAPEUTICS | 87,15 | -2,19 % | Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It | ||
| IMMUNOME | 25,070 | +1,27 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| ERASCA | 10,310 | +1,78 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,56 | +0,12 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| BIONTECH | 97,75 | +0,62 % | Moderna erneut mit Kurssprung, auch BioNTech gibt Gas - was ist da los? | Die Aktie von Moderna ging am Mittwoch mit einem Plus von fast 16 Prozent aus dem Handel. Damit gelang der Sprung auf ein neues 52-Wochen-Hoch. Auch die Aktie des deutschen Konkurrenten BioNTech verzeichnete... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,68 | +1,40 % | Piper Sandler raises Praxis Precision Medicines stock price target to $1,200 | ||
| RECURSION PHARMACEUTICALS | 4,320 | -3,36 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen |
PSYENCE GROUP INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,064 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE GROUP INC finden Sie auf Wallstreet Online.